UniQure reach­es mile­stone, Idor­si­a's bridge fi­nanc­ing ex­tends run­way, and Phar­varis scores $70M place­ment

UniQure, the de­vel­op­er of Hem­genix, the $3.5 mil­lion he­mo­phil­ia B gene ther­a­py li­censed to Aus­tralia’s CSL Behring, an­nounced Tues­day morn­ing that it hit a $100 mil­lion mile­stone based on Hem­genix’s first com­mer­cial sale in the US.

That mile­stone is set to be paid in the next 30 days.

This in­flux of cash comes a month af­ter uniQure sold part of its Hem­genix roy­al­ties to Health­Care Roy­al­ty and Sagard Health­care for $375 mil­lion, with the pos­si­bil­i­ty of a $25 mil­lion mile­stone pay­ment if sales reach a cer­tain amount in 2024.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER